Literature DB >> 23929838

Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut).

Jochen Greiner, Vanessa Schneider, Michael Schmitt, Marlies Götz, Konstanze Döhner, Markus Wiesneth, Hartmut Döhner, Susanne Hofmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23929838     DOI： 10.1182/blood-2013-04-496844

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  30 in total

Review 1.  Personal tumor antigens in blood malignancies: genomics-directed identification and targeting.

Authors:  Livius Penter; Catherine J Wu
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

2.  Leukemic stem cells of acute myeloid leukemia patients carrying NPM1 mutation are candidates for targeted immunotherapy.

Authors:  V Schneider; L Zhang; L Bullinger; M Rojewski; S Hofmann; M Wiesneth; H Schrezenmeier; M Götz; U Botzenhardt; T F E Barth; K Döhner; H Döhner; J Greiner
Journal:  Leukemia       Date:  2014-03-28       Impact factor: 11.528

Review 3.  Update on antigen-specific immunotherapy of acute myeloid leukemia.

Authors:  Sarah A Buckley; Roland B Walter
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

Review 4.  Cancer immune therapy for myeloid malignancies: present and future.

Authors:  Morten Orebo Holmström; Hans Carl Hasselbalch
Journal:  Semin Immunopathol       Date:  2018-07-09       Impact factor: 9.623

5.  Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition.

Authors:  Jochen Greiner; Susanne Hofmann; Michael Schmitt; Marlies Götz; Markus Wiesneth; Hubert Schrezenmeier; Donald Bunjes; Hartmut Döhner; Lars Bullinger
Journal:  Haematologica       Date:  2017-09-21       Impact factor: 9.941

6.  Systemic Immunotherapy Effective for Refractory Extramedullary Acute Myeloid Leukemia.

Authors:  Mansour Alfayez; Doina Ivan; Naveen Pemmaraju; Naval Daver; Courtney D DiNardo
Journal:  JCO Precis Oncol       Date:  2019-02-06

7.  Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.

Authors:  Dyantha I van der Lee; Rogier M Reijmers; Maria W Honders; Renate S Hagedoorn; Rob Cm de Jong; Michel Gd Kester; Dirk M van der Steen; Arnoud H de Ru; Christiaan Kweekel; Helena M Bijen; Inge Jedema; Hendrik Veelken; Peter A van Veelen; Mirjam Hm Heemskerk; J H Frederik Falkenburg; Marieke Griffioen
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

8.  Proteomic analysis of differentially expressed proteins in 5-fluorouracil-treated human breast cancer MCF-7 cells.

Authors:  J Cai; S Chen; W Zhang; Y Wei; J Lu; J Xing; Y Dong
Journal:  Clin Transl Oncol       Date:  2013-11-12       Impact factor: 3.405

9.  Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy.

Authors:  Hanna A Knaus; Sofia Berglund; Hubert Hackl; Amanda L Blackford; Joshua F Zeidner; Raúl Montiel-Esparza; Rupkatha Mukhopadhyay; Katrina Vanura; Bruce R Blazar; Judith E Karp; Leo Luznik; Ivana Gojo
Journal:  JCI Insight       Date:  2018-11-02

10.  CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia.

Authors:  Guozhu Xie; Nikola A Ivica; Bin Jia; Yingzhong Li; Han Dong; Yong Liang; Douglas Brown; Rizwan Romee; Jianzhu Chen
Journal:  Nat Biomed Eng       Date:  2020-10-12       Impact factor: 25.671
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.